We have been committed to furthering the understanding and treatment of pain for over 30 years. In this field, we have used our expertise in prolonged release technology to reduce the dosing frequency for patients, with the aim of ensuring continuous pain relief around the clock. This approach to providing round the clock pain control has been widely adopted both in the UK and internationally.
Since we launched our first product in this field, we have expanded our portfolio to include six medicines in 15 different formulations, each in a range of dose strengths, with the aim of providing health professionals with a broad range from which to select the most appropriate treatment for their patients.
Napp is passionately committed to the development of innovative oncology treatments and is currently focused on improving the options for those living with blood cancers.
Respiratory medicine was the first field in which we used our expertise in prolonged release technology. Our main business focus since then has been pain, but we are now renewing our commitment to respiratory medicine, focusing on treatments for asthma. We are committed to being a long-term partner in this field, using fresh thinking to provide patients with a new choice of treatments and disease management initiatives that will deliver patient benefit and real value to the NHS.
This is a new area for Napp, and we brought our first product to the UK market in 2010. In line with Napp’s expertise in prolonged release technology, this product incorporates a delivery mechanism that allows for timed release of the active ingredient.